RxSight, Inc.
NNASDAQ:RXSTCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Aziz Mottiwala
- Full Time Employees
- 461
- Sector
- Electronic technology
- Industry
- Electronic components
- Address
- 100 Columbia Aliso Viejo CA United States 92656
- IPO Date
- Jul 30, 2021
- CIK
- 0001111485
- Website
- rxsight.com
- Similar Companies
- Business
- RxSight, Inc. (Nasdaq: RXST) develops, manufactures and commercializes light adjustable intraocular lenses and related equipment for customized vision correction in cataract surgery patients; its proprietary RxSight system comprises the RxSight Light Adjustable Lens (LAL) and LAL+, photosensitive intraocular lenses that enable post-operative adjustments via ultraviolet light to optimize uncorrected visual acuity and correct low levels of astigmatism as low as 0.50 diopters; the RxSight Light Delivery Device (LDD), an office-based treatment console that delivers programmed UV light patterns to modify the LAL; and the RxSight Planner software for treatment planning. The company targets ophthalmologists and cataract surgeons serving premium intraocular lens (IOL) markets, primarily in the United States where it holds FDA approval and maintains an installed base exceeding 1,000 LDDs; it operates from headquarters in Aliso Viejo, California, founded in 1997 as Calhoun Vision, Inc. and renamed RxSight in February 2017. In recent developments, RxSight realigns its U.S. commercial organization by integrating clinical and sales teams to enhance LAL practice integration and launches new practice development programs leveraging insights from over 250,000 LAL cases; it enters international markets including South Korea and Singapore in 2025 while planning further expansion into Asia and Europe; preliminary 2024 results show full-year revenue of $139.9 million with 79% LAL procedure growth and issues 2025 revenue guidance of $185-$197 million alongside gross margin expansion to 71-73%.
Company News
RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
What RxSight (RXST) Said on Its Q3 Earnings Call
RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates
RxSight, Inc. Reports Third Quarter 2026 Results
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
RxSight (NASDAQ:RXST) and Organigram Global (NASDAQ:OGI) Financial Survey
Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)
RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical Analysis
85,838 Shares in RxSight, Inc. $RXST Purchased by Corient Private Wealth LP
BlackRock Inc. Purchases Shares of 5,790,408 RxSight, Inc. $RXST
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
Head-To-Head Comparison: RxSight (NASDAQ:RXST) and Futureworld (OTCMKTS:FWDG)
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight Q2 Earnings Call Highlights
RxSight Q2 Earnings Call Highlights
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook